Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Period	Debt/Equity
2015-12-31	0.68
2016-12-31	0.80
2017-12-31	1.68
2018-12-31	7.14
2019-12-31	-27.50
2020-12-31	3.71
2021-12-31	2.45
2022-12-31	-10.40
2023-12-31	-3.13
2024-12-31	-11.35

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CYTK	$64.59	-1.79%	1.36M
3
4
5

Cytokinetics Incorporated (CYTK) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Cytokinetics Incorporated Data in Excel

More CYTK Financial Data